Publication | Closed Access

Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)

Second-line TreatmentGastrointestinal OncologyAdvanced Gastric CancerMedicinePharmacologyGastroenterologyTcog Gi-0801/birip TrialPharmacotherapySurgeryCancer TreatmentOncologyRadiation Oncology